

CY 2024 Proposed Rates Compared to July 2023 Rates

Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs

CY 2023 FINAL Rates July 2023 Rates 06-29-2023

Updated 07/15/2023

Status	Opuateu 07/15/2025								
Indicator	Item/Code/Service		OPPS Pay	ment Sta	tus				
	Services furnished to a hospital outpatient that are paid under a payment system other than OPPS,* for example:	a fee schedule or	Not paid ur	nder OPP	S. Paid I	by MACs	under a fee schedule or	payment system other th	an OPPS.
Α	Separately Payable Clinical Diagnostic Laboratory Services deductible or coinsurance.)	(Not subject to					coinsurance unless		
İ	Unclassified drugs and biologicals reportable under HCPCS	code C9399					g or biological's av gnized compendiu		
D	Discontinued Codes		Not paid ur	nder OPP	S or any	other Me	dicare payment sy	ystem.	
	Items and Services:								
-4	Not covered by any Medicare outpatient benefit category								
E1	Statutorily excluded by Medicare		Not paid by	/ Medicare	e when s	ubmitted	on outpatient clair	ms (any outpatient	t bill type).
Ĭ	Not reasonable and necessary								
	Items and Services:								
E2	for which pricing information and claims data are not available		Not paid by	/ Medicare	when s	ubmitted	on outpatient clair	ms (any outpatien	t bill type).
G	Pass-Through Drug/ Biologicals		Paid under	OPPS; se	eparate A	APC payr	ment		
K	NonPass-Through Drugs and nonimplantable Biologicals, inclu Radiopharmaceuticals	ding Therapeutic	Paid under		·				
N	Items and Services packaged into APC rate		Paid under there is no				ed into payment fo	or other services.	Therefore,
							ays APC assignme	ents when service	s are
İ			separately	payable.					
İ							n the same claim	as a HCPCS code	e assigned
Q1	STV-Packaged Codes		status indic				vith specific combi	inations of service	s hased on
1			(2) Composite APC payment if billed with specific combinations of services OPPS composite-specific payment criteria. Payment is packaged into a sing						
			for specific combinations of services.						
									ment.
S T	Procedure or Service, Not Discounted When Multiple				•				
U	Significant Procedure, Multiple Procedure Reduction Applies Brachytherapy Sources		(3) In other circumstances, payment is made through a separate APC payment. Paid under OPPS; separate APC payment Paid under OPPS; separate APC payment Paid under OPPS; separate APC payment						
	Endonymorapy courses		r did diridor	0110,0	Sparate 7	и о рауг	Hone		
CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
38792	Injection procedure; <u>radioactive tracer</u> for identification of sentinel node		5591	5591	Q1	Q1	\$398.71	\$388.68	2.6%
20000	Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye, when								Providers should code
38900	performed (List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745)		N/A	N/A	N	Z	Packaged into APC rate	Packaged into APC rate	and bill so costs are realized for future rates
38900 49427	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510,		N/A	N/A N/A	N N	N N			costs are realized for future rates Providers should
	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745) Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological	erization for residual					APC rate Packaged into	APC rate	costs are realized for future rates Providers should code and bill so costs are realized for
49427	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745) Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological supervision and interpretation, see 75809, 78291) Insertion of non-indwelling bladder catheter (eg, straight catheter)		N/A	N/A	N	N	APC rate Packaged into APC rate	APC rate Packaged into APC rate	costs are realized for future rates Providers should code and bill so costs are realized for future rates
49427 51701	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745) Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological supervision and interpretation, see 75809, 78291) Insertion of non-indwelling bladder catheter (eg, straight cathet urine)	Foley)	N/A 5734	N/A 5734	N Q1	N Q1	Packaged into APC rate \$123.02	Packaged into APC rate	costs are realized for future rates Providers should code and bill so costs are realized for future rates 6.0%
49427 51701 51702	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745) Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological supervision and interpretation, see 75809, 78291) Insertion of non-indwelling bladder catheter (eg, straight cathet urine) Insertion of temporary indwelling bladder catheter; simple (eg, Insertion of temporary indwelling bladder catheter; complicated	Foley) l (eg, altered anatomy,	N/A 5734 5734	N/A 5734 5734	N Q1 Q1	N Q1 Q1	Packaged into APC rate \$123.02	Packaged into APC rate \$116.11	costs are realized for future rates Providers should code and bill so costs are realized for future rates 6.0% 6.0%
49427 51701 51702 51703	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745) Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological supervision and interpretation, see 75809, 78291) Insertion of non-indwelling bladder catheter (eg, straight cathet urine) Insertion of temporary indwelling bladder catheter; simple (eg, Insertion of temporary indwelling bladder catheter; complicated fractured catheter/balloon) Dual-energy X-ray absorptiometry, bone density study, 1 or mo	Foley) l (eg, altered anatomy,	N/A 5734 5734 5721	N/A 5734 5734 5721	N Q1 Q1 S	N Q1 Q1 S	Packaged into APC rate \$123.02 \$151.40	Packaged into APC rate \$116.11 \$116.11 \$145.43	costs are realized for future rates Providers should code and bill so costs are realized for future rates 6.0% 6.0% 4.1%
49427 51701 51702 51703 77080	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745) Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological supervision and interpretation, see 75809, 78291) Insertion of non-indwelling bladder catheter (eg, straight catheturine) Insertion of temporary indwelling bladder catheter; simple (eg, Insertion of temporary indwelling bladder catheter; complicated fractured catheter/balloon) Dual-energy X-ray absorptiometry, bone density study, 1 or mo (eg, hips, pelvis, spine)	Foley) I (eg, altered anatomy, ore sites; axial skeleton	N/A 5734 5734 5721 5522	N/A 5734 5734 5721 5522	N Q1 Q1 S	N Q1 Q1 S S	Packaged into APC rate \$123.02 \$123.02 \$151.40 \$106.04	Packaged into APC rate \$116.11 \$116.11 \$145.43 \$106.88	costs are realized for future rates Providers should code and bill so costs are realized for future rates 6.0% 6.0% 4.1% -0.8%
49427 51701 51702 51703 77080 77081	(List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) (Use in conjunction with 19302,19307,38500,38510, 38520,38525,38530,38542,38740,38745) Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological supervision and interpretation, see 75809, 78291) Insertion of non-indwelling bladder catheter (eg, straight catheturine) Insertion of temporary indwelling bladder catheter; simple (eg, Insertion of temporary indwelling bladder catheter; complicated fractured catheter/balloon) Dual-energy X-ray absorptiometry, bone density study, 1 or mo (eg, hips, pelvis, spine) Dxa bone density (peripheral) (eg, radius, wrist, heel) Dual-energy X-ray absorptiometry (DXA), bone density study,	Foley) (eg, altered anatomy, ore sites; axial skeleton 1 or more sites; axial seessment	N/A 5734 5734 5721 5522 5521	N/A 5734 5734 5721 5522 5521	N Q1 Q1 S S S	N Q1 Q1 S S S	Packaged into APC rate \$123.02 \$123.02 \$151.40 \$106.04	Packaged into APC rate \$116.11 \$116.11 \$145.43 \$106.88 \$86.88	costs are realized for future rates Providers should code and bill so costs are realized for future rates 6.0% 6.0% 4.1% -0.8%

CPT/	т	rade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description N	ame	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
NUCLEAR ME	EDICINE Modified in 2013 INTRODUCTORY SECTION - The se and therapeutic radiopharmaceutiacls nd dru								of diagnostic
	Thyroid uptake, single or multiple quantitative measurement(s) (in suppression, or discharge, when performed)	cluding stimulation,	5591	5591	S	S	\$398.71	\$388.68	2.6%
78013	Thyroid imaging (including vascular flow, when performed)		5591	5591	S	S	\$398.71	\$388.68	2.6%
78014	Thyroid imaging (including vascular flow, when performed); with s uptake(s) quantitative measurement(s) (including stimulation, sup discharge, when performed)		5591	5591	8	S	\$398.71	\$388.68	2.6%
78015	Thyroid carcinoma metastases imaging; limited are (eg, neck and	chest only)	5591	5591	S	S	\$398.71	\$388.68	2.6%
78016	Thyroid carcinoma metastases imaging; with additional studies (e	g, urinary recovery)	5591	5591	S	S	\$398.71	\$388.68	2.6%
78018	Thyroid carcinoma metastases imaging; whole body		5592	5592	S	S	\$523.96	\$504.50	3.9%
78020 + . add on	Thyroid carcinoma metastases uptake (Use in conjunction with co	ode 78018 only)	N/A	N/A	N	Z	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
78070 I	Parathyroid planar imaging (including subtraction, when performed	d)	5591	5591	S	S	\$398.71	\$388.68	2.6%
	Parathyroid planar imaging (including subtraction, when performed (SPECT)	d); with tomographic	5591	5591	S	S	\$398.71	\$388.68	2.6%
78072	Parathyroid planar imaging (including subtraction, when performer (SPECT), and concurrently acquired computed tomography (CT) localization		5592	5592	S	S	\$523.96	\$504.50	3.9%
78075	Adrenal imaging, cortex and/or medulla		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
	Unlisted endocrine procedure, diagnostic nuclear medicine		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Bone marrow imaging; limited area		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Bone marrow imaging; multiple areas		5591 5591	5591	S S	S S	\$398.71	\$388.68 \$388.68	2.6%
	Bone marrow imaging; whole body Plasma volume, radiopharmaceutical volume-dilution technique (s	separate procedure):		5591			\$398.71		
78110	single sampling Plasma volume, radiopharmaceutical volume-dilution technique (s		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
/8111 I	multiple sampling		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78120 I	Red cell volume determination (separate procedure); single samp	oling	5591	5591	S	S	\$398.71	\$388.68	2.6%
-	Red cell volume determination (separate procedure); multiple sar		5592	5592	S	S	\$523.96	\$504.50	3.9%
	Whole blood volume determination, including separate measurem volume and red cell volume (radiopharmaceutical volume-dilution		5592	5592	S	S	\$523.96	\$504.50	3.9%
	Red cell survival study;		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Red cell survival study; differential organ/tissue kinetics (eg, spler sequestration)	nic and/or hepatic	Deleted in 2021	Deleted in 2021	Đ	Đ	Deleted in 2021	Deleted in 2021	N/A
	Labeled red cell sequestration, differential organ/tissue, (eg, splen	nic and/or hepatic)	5591	5591	S	S	\$398.71	\$388.68	2.6%
/8185	Spleen imaging only, with or without vascular flow (If combined wi procedures 78215 and 78216)	th liver study, use	5591	5591	S	S	\$398.71	\$388.68	2.6%
78191	Platelet survival study		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Lymphatics and lymph nodes imaging (For sentinel node identifica scintigraphy imaging, use 38792)	ation without	5592	5592	S	S	\$523.96	\$504.50	3.9%
	Unlisted hematopoietic, Reticuloendothelial and lymphatic proced nuclear medicine	ure, diagnostic	5591	5591	S	S	\$398.71	\$388.68	2.6%
78201 I	Liver imaging; static only		5592	5592	S	S	\$523.96	\$504.50	3.9%
78202 I	Liver imaging; with vascular flow		5592	5592	S	S	\$523.96	\$504.50	3.9%
78215 I	Liver and spleen imaging; static only		5591	5591	S	S	\$398.71	\$388.68	2.6%
78216 I	Liver and spleen imaging; with vascular flow		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Hepatobiliary system imaging, including gallbladder when present		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Hepatobiliary system imaging, including gallbladder when present pharmacologic intervention, including quantitative measurement(s		5592	5592	S	S	\$523.96	\$504.50	3.9%
78230	Salivary gland imaging;		5591	5591	S	S	\$398.71	\$388.68	2.6%
-	Salivary gland imaging; with serial images		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Salivary gland function study		5591	5591	S	S	\$398.71	\$388.68	2.6%
-	Esophageal motility Contribution muscos imaging		5591	5591	S	S	\$398.71	\$388.68	2.6%
	Gastric mucosa imaging		5591	5591	S	S	\$398.71	\$388.68	2.6%
-			5501	5501	Q	9	\$308 71	\$388 68	2 6%
78262	Gastroesophageal reflux study Gastric Emptying Imaging Study (eg, solid, liquid or both)		5591 5591	5591 5591	S	S S	\$398.71 \$398.71	\$388.68 \$388.68	2.6% 2.6%

CPT/	т	rade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description N	lame	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
78266	Gastric Emptying Imaging Study (eg, solid, liquid or both); with sr transit, multiple days	mall bowel and colon	5592	5592	s	S	\$523.96	\$504.50	3.9%
78267	Urea breath test, C-14 (isotopic); acquisition for analysis		N/A	N/A	Α	А	N/A	N/A	N/A
78268	Urea breath test, C-14 (isotopic); analysis		N/A	N/A	А	A	N/A	N/A	N/A
	Acute gastrointestinal blood loss imaging		5591	5591	s	S			
78278							\$398.71	\$388.68	2.6%
78282	Gastrointestinal protein loss		5591	5591	S	S	\$398.71	\$388.68	2.6%
78290	Intestine imaging (eg, ectopic gastric mucosa, Meckel's localization	on, volvulus)	5591	5591	S	S	\$398.71	\$388.68	2.6%
78291	Peritoneal-venous shunt patency test (eg, for LeVeen, Denver sh	nunt)	5591	5591	S	S	\$398.71	\$388.68	2.6%
78299	Unlisted gastrointestinal procedure, diagnostic nuclear medicine		5591	5591	S S	S	\$398.71	\$388.68	2.6%
78300 78305	Bone and/or joint imaging; limited area		5591 5591	5591 5591	S	S	\$398.71	\$388.68	2.6%
	Bone and/or joint imaging; multiple areas						\$398.71	\$388.68	
78306	Bone and/or joint imaging; whole body		5591	5591	S	S	\$398.71	\$388.68	2.6%
78315	Bone and/or joint imaging; 3 three phase study		5591	5591	S	S	\$398.71	\$388.68	2.6%
78350	Bone density (bone mineral content) study , 1 or more sites; single absorptiometry	le photon	N/A	N/A	E1	E1	N/A	N/A	N/A
78351	Bone density (bone mineral content) study , 1 or more sites; dual absorptiometry one or more sites	photon	N/A	N/A	E1	E1	N/A	N/A	N/A
78399	Unlisted musculoskeletal procedure, diagnostic nuclear medicine	.	5591	5591	s	S	\$398.71	\$388.68	2.6%
78414	Determination of central c-v hemodynamics (non-imagine) (eg, ej probe technique) with or without pharmacologic intervention or exmultiple determinations		5592	5592	S	S	\$523.96	\$504.50	3.9%
78428	Cardiac shunt detection		5591	5591	S	S	\$398.71	\$388.68	2.6%
78429	Myocrd img pet 1 std w/ct Myocardial imaging, positron emission tomography (PET), metab (including ventricular wall motion(s), and/or ejection fraction(s), w single study; with concurrently acquired computed tomography tr	hen performed)	5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
78430	Myocardial imaging, positron emission tomography, perfusion stuventricular wall motion(s), and/or ejection fractions(s), when perfusidny, at rest or stress (exercise or pharmacologic), with corcomputed tomography transmission scan	ormed); single	5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
78431	Myocardial imaging, positron emission tomography, perfusion stuventricular wall motion(s), and/or ejection fractions(s), when perfusions at rest and stress (exercise or pharmacologic), with acquired computed tomography transmission scan	ormed); multiple	1522	1523	s	S	\$2,250.50	\$2,750.50	-18.2%
78432	Myocrd img pet 2rtracer Myocardial imaging, positron emission tomography, combined pe metabolic evaluation study (including ventricular wall motion(s), a fraction(s), when performed), dual radiotracer (eg, myocardial	and/or ejection	1518	1520	S	S	\$1,650.50	\$1,850.50	-10.8%
78433	Myocrd img pet 2rtracer ct Myocardial imaging, positron emission tomography, combined pe metabolic evaluation study (including ventricular wall motion(s), a fraction(s), when performed), dual radiotracer (eg, myocardial vi concurrently acquired computed tomography transmission s	and/or ejection iability); with	1521	1521	S	S	\$1,950.50	\$1,950.50	0.0%
78434 + add on	Absolute quantitation of myocardial blood flow (AQMBF), positror tomography (PET), rest and pharmacologic stress (List separatel for primary procedure) (Use 78434 in conjunction with 78431, 784 calcium scoring, use 75571)	ly in addition to code	N/A	N/A	N	N	Packaged into APC rate is part of new technology payment	Packaged into APC rate is part of new technology payment	Providers should code and bill so costs are realized for future rates
78445	Non-cardiac vascular flow imaging (ie, angiography, venography))	5591	5591	s	s	\$398.71	\$388.68	2.6%
78451	Myocardial perfusion imaging, tomographic (SPECT) (including a correction, qualitative or quantitative wall motion, ejection fraction gated technique, additional quantification, when performed); single stress (exercise or pharmacologic)	n by first pass or	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78452	Myocardial perfusion imaging, tomographic (SPECT) (including a correction, qualitative or quantitative wall motion, ejection fractior gated technique, additional quantification, when performed); mult and/or stress (exercise or pharmacologic) and/or redistribution ar	n by first pass or iple studies, at rest	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
•+0742T	Absolute quantitation of myocardial blood flow (AQMBF), single-procomputed tomography (SPECT), with exercise or pharmacologic when performed (List separately in addition to code for primary processes to the content of the code of the	stress, and at rest,	NC	N/A	NC = new code	N	Packaged into APC rate is part of primary service payment	N/A	Providers should code and bill so costs are realized for future rates

CPT/	1	Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description N	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
78453	Myocardial perfusion imaging, planar (including qualitative or qua- ejection fraction by first pass or gated technique, additional quan performed); single study, at rest or stress (exercise or pharmaco	tification, when	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78454	Myocardial perfusion imaging, planar (including qualitative or qua ejection fraction by first pass or gated technique, additional quan performed); multiple studies, at rest and/or stress (exercise or pr redistribution and/or rest reinjection	tification, when	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78456	Acute venous thrombus imaging, peptide		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78457	Venous thrombosis imaging, venogram; unilateral		5592	5592	S	S	\$523.96	\$504.50	3.9%
78458	Venous thrombosis imaging, venogram; bilateral		5591	5591	S	S	\$398.71	\$388.68	2.6%
78459	Myocardial imaging, positron emission tomography (PET), metal (including ventricular wall motion(s), and/or ejection fraction(s), visingle study		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78466	Myocardial imaging, infarct avid, planar; qualitative or quantitativ	е	5591	5591	S	S	\$398.71	\$388.68	2.6%
78468	Myocardial imaging, infarct avid, planar; with ejection fraction by	first pass technique	5592	5592	S	S	\$523.96	\$504.50	3.9%
78469	Myocardial imaging, infarct avid, planar; tomographic SPECT wit quantification	th or without	5592	5592	S	S	\$523.96	\$504.50	3.9%
78472	Cardiac blood pool imaging, gated equilibrium; planar, single sture (exercise and/or pharmacologic), wall motion study plus ejection without additional quantitative processing (or assessment of care pass technique, use 78496)	fraction, with or	5591	5591	S	S	\$398.71	\$388.68	2.6%
78473	Cardiac blood pool imaging, gated equilibrium; multiple studies, vejection fraction, at rest and stress (exercise and/or pharmacolog additional quantification		5591	5591	S	s	\$398.71	\$388.68	2.6%
78481	Cardiac blood pool imaging (planar), first pass technique; single stress (exercise and/or pharmacologic), wall motion study plus e or without quantification		5592	5592	S	S	\$523.96	\$504.50	3.9%
78483	Cardiac blood pool imaging (planar), first pass technique; multipl with stress (exercise and/or pharmacologic), wall motion study p with or without quantification		5592	5592	S	S	\$523.96	\$504.50	3.9%
78491	Myocardial imaging, positron emission tomography, perfusion str ventricular wall motion(s), and/or ejection fractions(s), when perf study, at rest or stress (exercise or pharmacologic)		5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
#78430	Myocardial imaging, positron emission tomography, perfusion stuventricular wall motion(s), and/or ejection fractions(s), when perfudy, at rest or stress (exercise or pharmacologic), with cocomputed tomography transmission scan	ormed); single	5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
78492	Myocardial imaging, positron emission tomography, perfusion structure wall motion(s), and/or ejection fractions(s), when perfusions at rest and stress (exercise or pharmacologic)		5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
#78431	Myocardial imaging, positron emission tomography, perfusion structure wall motion(s), and/or ejection fractions(s), when perfusions at rest and stress (exercise or pharmacologic), with acquired computed tomography transmission scan	ormed); multiple	1522	1523	S	S	\$2,250.50	\$2,750.50	-18.2%
#78432	Myocrd img pet 2rtracer Myocardial imaging, positron emission tomography, combined pr metabolic evaluation study (including ventricular wall motion(s), fraction(s), when performed), dual radiotracer (eg, myocardial	and/or ejection	1518	1520	S	S	\$1,650.50	\$1,850.50	-10.8%
#78433	Myocrd img pet 2rtracer ct Myocardial imaging, positron emission tomography, combined per metabolic evaluation study (including ventricular wall motion(s), fraction(s), when performed), dual radiotracer (eg, myocardial v	and/or ejection viability); with	1521	1521	S	S	\$1,950.50	\$1,950.50	0.0%
#78434 + add on	Absolute quantitation of myocardial blood flow (AQMBF), positro tomography (PET), rest and pharmacologic stress (List separate for primary procedure) (Use 78434 in conjunction with 78431, 78 calcium scoring, use 75571)	ly in addition to code	N/A	N/A	Ν	N	Packaged into APC rate is part of new technology payment	Packaged into APC rate is part of new technology payment	Providers should code and bill so costs are realized for future rates
78494	Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, v ejection fraction, with or without quantitative processing	vall motion study plus	5591	5591	S	S	\$398.71	\$388.68	2.6%
78496+ add on	Cardiac blood pool imaging, gated equilibrium, single study, at reventricular ejection fraction by first pass technique (Use 78496 in 78472)		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers shou code and bill s costs are realized for future rates
78499	Unlisted cardiovascular procedure, diagnostic nuclear medicine		5591	5591	S	S	\$398.71	\$388.68	2.6%

CPT/	Tra	ade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description Na	ame	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
0331T	Myocardial sympathetic innervation, imaging, planar qualitative ass	sessment	5593	5593	S	s	\$1,373.83	\$1,327.27	3.5%
0332T	Myocardial sympathetic innervation, imaging, planar qualitative and assessment; with tomographic SPECT	d quantitative	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78579	Pulmonary ventilation imaging (eg, aerosol or gas)		5591	5591	S	S	\$398.71	\$388.68	2.6%
78580	Pulmonary perfusion imaging (eg, particulate)		5591	5591	S	S	\$398.71	\$388.68	2.6%
78582	Pulmonary ventilation imaging (eg, aerosol or gas) and perfusion ir	maging	5592	5592	S	S	\$523.96	\$504.50	3.9%
78597	Quantitative differential pulmonary perfusion, including imaging who	en performed	5591	5591	S	S	\$398.71	\$388.68	2.6%
78598	Quantitative differential pulmonary perfusion and ventilation (eg ae including imaging when performed	rosol or gas),	5592	5592	S	S	\$523.96	\$504.50	3.9%
78599	Unlisted respiratory procedure, diagnostic nuclear medicine		5591	5591	S	S	\$398.71	\$388.68	2.6%
78600	Brain imaging, less than 4 static views;		5591	5591	S	S	\$398.71	\$388.68	2.6%
78601	Brain imaging, less than 4 static views; with vascular flow		5591	5591	S	S	\$398.71	\$388.68	2.6%
78605	Brain imaging, minimum 4 static views;		5592	5592	S	S	\$523.96	\$504.50	3.9%
78606	Brain imaging, minimum 4 static views; with vascular flow		5592	5592	S	S	\$523.96	\$504.50	3.9%
78608	Brain imaging, positron emission tomography (PET); metabolic eva	aluation	5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
78609	Brain imaging, positron emission tomography (PET); perfusion eva	aluation	N/A	N/A	E1	E1	N/A	N/A	N/A
78610	Brain imaging, vascular flow only		5592	5592	S	S	\$523.96	\$504.50	3.9%
78630	Cerebrospinal fluid flow, imaging (not including introduction of mate cisternography (For injection procedure, see 61000-61070, 62270-		5592	5592	S	S	\$523.96	\$504.50	3.9%
78635	Cerebrospinal fluid flow, imaging (not including introduction of mate ventriculography (For injection procedure, see 61000-61070, 62270)		5592	5592	S	S	\$523.96	\$504.50	3.9%
78645	Cerebrospinal fluid flow, imaging (not including introduction of mate evaluation (For injection procedure, see 61000-61070, 62270-6229		5592	5592	S	S	\$523.96	\$504.50	3.9%
78650	Cerebrospinal fluid leakage detection and localization		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78660	Radiopharmaceutical dacryocystography		5591	5591	S	S	\$398.71	\$388.68	2.6%
78699	Unlisted nervous system procedure, diagnostic nuclear medicine		5591	5591	S	S	\$398.71	\$388.68	2.6%
78700	Kidney imaging morphology		5591	5591	S	S	\$398.71	\$388.68	2.6%
78701	Kidney imaging morphology with vascular flow		5591	5591	S	S	\$398.71	\$388.68	2.6%
78707	Kidney imaging morphology with vascular flow and function, single pharmacological intervention	study without	5592	5592	S	S	\$523.96	\$504.50	3.9%
78708	Kidney imaging morphology with vascular flow and function, single pharmacological intervention (eg, angiotensin converting enzyme in diuretic)	•	5592	5592	S	S	\$523.96	\$504.50	3.9%
78709	Kidney imaging morphology with vascular flow and function, multip without pharmacological intervention (eg, angiotensin converting el and/or diuretic)		5592	5592	S	S	\$523.96	\$504.50	3.9%
78725	Kidney function study, non-imaging radioisotopic study		5591	5591	S	S	\$398.71	\$388.68	2.6%
78730 + add on	Urinary bladder residual study (List separately in addition to code for procedure) (Use 78730 in conjunction with 78740) (For measuremersidual urine and/or bladder capacity by ultrasound, nonimaging, ultrasound imaging of the bladder only, with measurement of postv when performed, use 76857)	ent of postvoid use 51798) (For	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
78740	Ureteral reflux study (radiopharmaceutical voiding cystogram) For 51701, 51702, 51703	catheterization see	5591	5591	S	S	\$398.71	\$388.68	2.6%
78761	Testicular imaging with vascular flow		5591	5591	S	S	\$398.71	\$388.68	2.6%
78799	Unlisted genitourinary procedure; diagnostic nuclear medicine		5591	5591	S	S	\$398.71	\$388.68	2.6%
78800	Radiopharmaceutical localization of tumor, inflammatory process o radiopharmaceutical agent(s) (includes vascular flow and blood po performed); planar, single area (eg, head, neck, chest, pelvis), sing	ol imaging, when	5591	5591	S	S	\$398.71	\$388.68	2.6%
78801	Radiopharmaceutical localization of tumor, inflammatory process o radiopharmaceutical agent(s) (includes vascular flow and blood po performed); planar, 2 or more areas (eg, abdomen and pelvis, hearmore days imaging or single area imaging over 2 or more days	ol imaging, when	5591	5591	S	S	\$398.71	\$388.68	2.6%
78802	Radiopharmaceutical localization of tumor, inflammatory process or radiopharmaceutical agent(s), (includes vascular flow and blood poperformed); planar, whole body, single day of imaging		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%

MCPCS Description Name APC APC SI SI Psyment Rate	CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
AP78000 price production of th	CPCS	Description	Name	APC	APC		SI	Payment Rate	Payment Rate	Change
Redisplanmaceutical postulation of burnor, inflammatory process or distribution of activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation and activation activation and activation activation and activation activation and activation activation activation and activation a	#78803 rad	adiopharmaceutical agent(s), (includes vascular flow and blood performed); tomographic (SPECT) single area (eg. Head, neck	d pool imaging when	5593	5593	s	S	\$1,373.83	\$1,327.27	3.5%
erationary Pleasin, who both, 2 or more days imaging Ro locity turn speed 2 areas Radiopharmaceutical socialisation of turnor, inflammatory process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging when single process or distribution of imaging or single area or acquisitions, over 2 or more days Ro locity turn speed wid 2 Ro locity turn speed wid 2 Ro locity turn speed wid 2 Robotic process or distribution of turnor, inflammatory process or distribution of real process or distribution of turnor, inflammatory process or or distribution of turnor, inflammatory process or or distribution of turnor, inflammatory process or or distribution of turnor, inflammatory process or or distribution of turnor, inflammatory process or or or or or or or or or or or or or	#78830 pe to	Radiopharmaceutical localization of tumor, inflammatory process adiopharmaceutical agent(s), (includes vascular flow and bloo- berformed); tomographic (SPECT) with concurrently acquire comography (CT) transmission scan for anatomical review, determination/detection of pathology, single area (eg, head	d pool imaging when ed computed localization and	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
A#78831 A#78837 A#78837 A#78838 A#78839 A#7883	78804 rad	adiopharmaceutical agent(s), (includes vascular flow and blood		5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical parells, (includes vascular flow and blood pool imaging when performed); temographic (SPECT) with concurrently acquired computed to prography (CT) transmission scan for anatomical review, localization and determination/detection of particulary, areas (eg. pelvis and knees, cheart and abdomen). or saparate accusitions (so. flow prography concurrently acquired computed to particular), single day of imaging, or single area or accusisition, over 2 or more day. 78808 Injection proceduse for radiopharmaceutical localization by non-imaging probe study, (For sentinel lymph node identification, use 38792) 78811 Positron emission tomography (PET) imaging; limited area (eg. chest, head/neck) 5594	#78831 Ra pe an	Radiopharmaceutical localization of tumor, inflammatory proces adiopharmaceutical agent(s), (includes vascular flow and blood performed); tomographic (SPECT), minimum 2 areas (eg, pe and abdomen), or separate acquisitions (eg, lung ventilatio	d pool imaging when elvis and knees, <u>chest</u> n and perfusion),	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
Transport Tran	#78832 to de ch	Radiopharmaceutical localization of tumor, inflammatory process adiopharmaceutical agent(s), (includes vascular flow and blook performed); tomographic (SPECT) with concurrently acquire omography (CT) transmission scan for anatomical review, determination/detection of pathology, minimum 2 areas (egchest and abdomen), or separate acquisitions (eq. lung verberfusion), single day of imaging, or single area or acquisitions.	d pool imaging when ed computed localization and pelvis and knees, stilation and	5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
Positron emission tomography (PET) imaging; skull base to mid-thigh Positron emission tomography (PET) maging; whole body Positron emission tomography (PET) maging; whole body Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; middle area (eg., class), headineck) Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (TO) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (TO) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (TO) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (TO) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed determination/detection of pathology, minimum 2 areas (eg. pelvis and knees, characterial pagents), includes vascular flow and blood pool imaging when performed); tomographic (PET) with concurrently acquired computed determination/detection of pathology, minimum 2 areas (eg. pelvis and knees, characterial pagents), includes vascular flow and blood pool imaging when performed); tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acq	78808 int	ntravenous (eg, parathyroid adenoma)	imaging probe study,	5591	5591	Q1	Q1	\$398.71	\$388.68	2.6%
Positron emission tomography (PET) imaging; whole body Positron emission tomography (PET) with concurrently acquired computed computed computed tomography (CT) for attenuation correction and anatomical localization imaging; imited area (eg., chest, headineck). Positron emission tomography (PET) with concurrently acquired computed comparably (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh base to mid-thigh tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed comparable (PET) with concurrently acquired computed determination/detection of pathology, minimum 2 areas (eg., pelvis and knees, petal-graph) (PET) with concurrently acquired computed determination/detection of pathology, minimum 2 areas (eg., pelvis and knees, petal-graph). Packaged into APC rate and additionally of particular and particular and particular and particular acquisitions (eg., lung ventilation and particular and particular acquisitions (eg., lung ventilation and particular and particular acquisitions (eg., lung ventilation and particular and particular acquisitions (eg., lung ventilation and particular and particular acquisitions (eg., lung ventilation and particular and particular acquisitions (eg., lung v	78811 Pc	Positron emission tomography (PET) imaging; limited area (eg.	chest, head/neck)	5593	5593	s	s	\$1,373.83	\$1,327.27	3.5%
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging: initial area (eg., bests, headrines). Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired tomography (PET) with post (PET) with concurrently acquired tomography (PET) with post (PET) with acquired tomography (PET) with concurrently acquired tomography (PET) with post (PET) with concurrently acquired tomography (PET) with post (PET) with acquired tomography (PET) with concurrently acquired tomography (PET) with post (PET)	78812 Pc	Positron emission tomography (PET) imaging; skull base to mic	d-thigh	5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
tomography (CT) for attenuation correction and anatomical localization imaging: limited area (eg., beets, head/neck) Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull brown by the concurrent to the concurrent type of the concurrent type	78813 Pc	Positron emission tomography (PET) imaging; whole body		5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body Rp lociz] tum spect 2 areas Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s), (includes vascular flow and blood pool imaging when performed); tomographic (SPECT), minimum 2 areas (eg., pelvis and knees, chest and abdomen), or separate acquisitions (eg., lung ventilation and perfusion). single day of imaging, or single area or acquisition, over 2 or more days A#78832 tomographic (SPECT) with concurrently acquired computed tomography (CT) transmissions scan for anatomical review, localization and perfusion). single day of imaging, or single area or acquisition, over 2 or more days Rp lociz] tum spect wict 2 Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical localization for tumor, inflammatory process or distribution of radiopharmaceutical localization for uncorrently acquired computed tomography (CT) transmissions scan for anatomical review, localization and perfusion), single day of imaging, or single area or acquisition, over 2 or more days Rp quan meas single area Rp quantitation is more than 1 day or more than 1 area) Rp packaged into APC rate Redicipharmaceutical therapy, by oreal administration (Expressopological antithody by	78814 tor	omography (CT) for attenuation correction and anatomical loca		5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
##78831 homography (CT) for attenuation correction and anatomical localization imaging; whole body Rp locizy turn spect 2 areas Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s), (includes vascular flow and blood pool imaging when performed); tomographic (SPECT), minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg. luny ventilation and performed); tomographic (SPECT) with concurrently acquired computed tomography (CT) transmission scan for anatomical review, localization and perfusion), single day of imaging, or single area or acquisitions (eg., lung ventilation and perfusion), single day of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg., lung ventilation and perfusion), single day of imaging, or single area or acquisition, over 2 or more days ##78832 tomography (CT) transmission scan for anatomical review, localization and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg., lung ventilation and perfusion), single day of imaging, or single area or acquisition, over 2 or more days ##78835 + add on (Use 78835 in conjunction with 78830, 78832) (Report multiple units of 78835 if quantitation is more than 1 day or more than 1 area) ##78990 Unlisted miscellaneous procedure, diagnostic nuclear medicine ##78990 Unlisted miscellaneous procedure, diagnostic nuclear medicine ##78990 Radiolabeled product provided during a hospital inpatient stay ##78990 Radiolabeled product provided during a hospital inpatient stay ##78990 Radiolabeled product provided during a hospital inpatient stay ##78990 Radiolabeled product provided during a hospital inpatient stay ##78990 Radiolabeled product provided during a hospital inpatient stay	78815 tor	omography (CT) for attenuation correction and anatomical loca		5594	5594	s	S	\$1,507.82	\$1,489.35	1.2%
Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s), (includes vascular flow and blood pool imaging when performed); tomographic (SPECT), minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and perfusion), single day of imaging, or single area or acquisition, over 2 or more days Rp locizj tum spect Wict 2 Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical localization and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and determination/detection of pathology, minimum 2 areas (eg, pelvis and k	78816 tor	omography (CT) for attenuation correction and anatomical loca		5594	5594	s	S	\$1,507.82	\$1,489.35	1.2%
Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s), (includes vascular flow and blood pool imaging when performed); tomographic (SPECT) with concurrently acquired computed tomography (CT) transmission scan for anatomical review, localization and determination/detection of pathology, minimum 2 areas (eg, pelvis and knees, chest and abdomen), or separate acquisitions (eg, lung ventilation and perfusion), single day of imaging, or single area or acquisition, over 2 or more days Rp quan meas single area NEW FOR 2020 Radiopharmaceutical quantification measurement(s) single area (Use 78835 in conjunction with 78830, 78832) (Report multiple units of 78835 if quantitation is more than 1 day or more than 1 area) N/A N/A N/A N Packaged into APC rate Packaged into APC rate Packaged into APC rate Packaged into APC rate Packaged into APC rate Packaged into APC rate Packaged into APC rate	#78831 Ra pe	Radiopharmaceutical localization of tumor, inflammatory proces adiopharmaceutical agent(s), (includes vascular flow and blood performed); tomographic (SPECT), minimum 2 areas (eg, pe and abdomen), or separate acquisitions (eg, lung ventilatio	d pool imaging when elvis and knees, <u>chest</u> n and perfusion),	5593	5593	S	S	\$1,373.83	\$1,327.27	3.5%
78835 + Add on VEW FOR 2020 Radiopharmaceutical quantification measurement(s) single area (Use 78835 in conjunction with 78830, 78832) (Report multiple units of 78835 if quantitation is more than 1 day or more than 1 area) N/A N/A N/A N Packaged into APC rate Packaged into APC rate Packaged into APC rate Radiolabeled product provided during a hospital inpatient stay N/A N/A N/A N Packaged into APC rate Packaged into APC rate	#78832 too de ch	Radiopharmaceutical localization of tumor, inflammatory process adiopharmaceutical agent(s), (includes vascular flow and blook performed); tomographic (SPECT) with concurrently acquire omography (CT) transmission scan for anatomical review, determination/detection of pathology, minimum 2 areas (egchest and abdomen), or separate acquisitions (eg. lung verberfusion), single day of imaging, or single area or acquisitions.	d pool imaging when ed computed localization and pelvis and knees, stilation and	5594	5594	S	S	\$1,507.82	\$1,489.35	1.2%
C9898 Radiolabeled product provided during a hospital inpatient stay N/A N/A N N Packaged into APC rate Packaged into APC rate	8835 + NE add on (U	VEW FOR 2020 Radiopharmaceutical quantification measurem Use 78835 in conjunction with 78830, 78832) (Report multiple		N/A	N/A	N	N		Packaged into APC rate	Providers should code and bill so costs are realized for future rates
Radiopharmaceutical therapy, by oral administration (For monoclonal antibody by	78999 Ur	Jnlisted miscellaneous procedure, diagnostic nuclear medicine	•	5591	5591	S	S	\$398.71	\$388.68	2.6%
Parlionharmaceutical therapy, by oral administration (For monoclonal antibody by	09898 Ra	Radiolabeled product provided during a hospital inpatient stay		N/A	N/A	N	N		Packaged into APC rate	Providers should code and bill so costs are realized for future rates
79005 Readiophial maceutical interapy, by oral administration (For monocional antibody by intravenous infusion, use 79403) S S \$246.37 \$249.73		Radiopharmaceutical therapy, by oral administration (For mono ntravenous infusion, use 79403)	clonal antibody by	5661	5661	S	S	\$246.37	\$249.73	-1.3%

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
79101	Radiopharmaceutical therapy, by intravenous administration (Econjunction with 36400, 35410, 79403, 90780, 96408) (For mo intravenous infusion, use 79403) (For infusion or instillation of radioelement solution that includes three months follow-up care	noclonal antibody by non-antibody	5661	5661	S	S	\$246.37	\$249.73	-1.3%
79200	Radiopharmaceutical therapy, by intracavitary administration		5661	5661	S	S	\$246.37	\$249.73	-1.3%
79300	Radiopharmaceutical therapy, by interstitial radioactive colloid	administration	5661	5661	S	S	\$246.37	\$249.73	-1.3%
79403	Radiopharmaceutical therapy, radiolabeled monoclonal antibod infusion (For pre-treatment imaging, see 78802, 78804) (Do no with 79101)		5661	5661	S	S	\$246.37	\$249.73	-1.3%
79440	Radiopharmaceutical therapy, by intra-articular administration		5661	5661	S	S	\$246.37	\$249.73	-1.3%
79445	Radiopharmaceutical therapy, by intra-arterial particulate admit 79445 in conjunction with 90783, 96420) (Use appropriate procsupervision and interpretation codes for the angiographic and i procedures provided pre-requisite to intra-arterial radiopharma	cedural and radiological nterventional	5661	5661	S	S	\$246.37	\$249.73	-1.3%
79999	Radiopharmaceutical therapy, unlisted procedure		5661	5661	S	S	\$246.37	\$249.73	-1.3%
93017	Cardiovascular stress test using maximal or submaximal tread continuous electrocardiographic monitoring, and/or pharmacolonly, without interpretation and report		5722	5722	Q1	Q1	\$304.35	\$280.06	8.7%
96413	Chemotherapy administration, intravenous infusion technique; or initial substance/drug	up to one hour, single	5694	5694	S	S	\$334.39	\$332.62	0.5%
G0219	PET imaging whole body; melanoma for non-covered indication	ns	N/A	N/A	E1	E1	N/A	N/A	N/A
G0235	PET IMAGING, ANY SITE, NOT OTHERWISE SPECIFIED		5591	5591	S	S	\$398.71	\$388.68	2.6%
G0252	PET imaging, full & partial-ring PET scanner only, for initial dia and/or surgical planning for breast cancer (eg, initial staging of		N/A	N/A	E1	E1	N/A	N/A	N/A
F	RADIOPHARMACEUTICALS & NUCLEAR MEDICINE RELATE	ED DRUGS	APC PR 23	APC Jul 22	SI PR 23	SI Jul 22	2023 Proposed	2023 July	% Change
Q9969	Non-HEU TC-99M Add-On per study dose Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose	95 percent NON-HEU Product	1442	1442	К	К	\$10.00	\$10.00	0.0%
Q9982	Flutemetamol f18 diagnostic Flutemetamol F-18, diagnostic, per study dose, up to 5 millicuries	Vizamyl™ G.E. NDC # 17156-067-30	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers shoul code and bill so costs are realized for future rates
Q9983	Florbetaben f18 diagnostic Florbetaben F-18, diagnostic, per study dose, up to 8.1 millicuries	Neuracec™ Life Molecular Imaging (formerly Piramal) NDC # 54828-001-30	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers shoul code and bill so costs are realized for future rates
A4641	Radiopharm dx agent noc RADIOPHARMACEUTICAL, DIAGNOSTIC, NOT OTHERWISE CLASSIFIED	NOC	N/A	N/A	Z	N	Packaged into APC rate	Packaged into APC rate	Providers shoul code and bill so costs are realized for future rates
A4642	In111 satumomab INDIUM IN-111 SATUMOMAB PENDETIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 6 MILLICURIES	ONCOSCINT®	N/A	N/A	Z	N	Packaged into APC rate	Packaged into APC rate	Providers shoul code and bill so costs are realized for future rates
A9500	Tc99m sestamibi TECHNETIUM TC-99M SESTAMIBI, DIAGNOSTIC, PER STUDY DOSE, UP TO 40 MILLICURIES	CARDIOLITE® / MIRALUMA®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers shoul code and bill so costs are realized for future rates
A9501	Technetium TC-99m teboroxime TECHNETIUM TC-99M TEBOROXIME, DIAGNOSTIC, PER STUDY DOSE	CardioTec® TEBO	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9502	Tc99m tetrofosmin TECHNETIUM TC-99M TETROFOSMIN, DIAGNOSTIC, PER STUDY DOSE	MYOVIEW®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers shoul code and bill so costs are realized for future rates
A9503	Tc99m medronate TECHNETIUM TC-99M MEDRONATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 30 MILLICURIES	MDP	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
A9504	Tc99m apcitide TECHNETIUM TC-99M APCITIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 20 MILLICURIES	ACUTECT®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9505	TL201 thallium THALLIUM TL-201 THALLOUS CHLORIDE, DIAGNOSTIC, PER MILLICURIE	THALLIUM 201	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9507	In111 capromab INDIUM IN-111 CAPROMAB PENDETIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MILLICURIES	PROSTASCINT®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9508	I131 iodobenguate, dx IODINE I-131 IOBENGUANE SULFATE, DIAGNOSTIC, PER 0.5 MILLICURIE	I-131 MIBG	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9509	Iodine I-123 sod iodide mil IODINE I-123 SODIUM IODIDE, DIAGNOSTIC, PER MILLICURIE	Use for 1-4 mCi doses of I-123 for whole body imaging for less than 1 mCi and thyroid imaging see A9516	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9510	Tc99m disofenin TECHNETIUM TC-99M DISOFENIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES	DISIDA	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9512	Tc99m pertechnetate TECHNETIUM TC- 99M PERTECHNETATE, DIAGNOSTIC, PER MILLICURIE	Straight Tech Technescan Technelite	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9513	Lutetium Lu 177 dotatate,tx Lutetium Lu 177, dotatate, therapeutic, 1 mCi	LUTATHERA® Pass-through July 1, 2018 to June 30, 2021 then separate payment (K) therapeutic Prior code C9031	9067	9067	К	К	\$282.28	\$289.98	-2.7%
A9515	Choline c-11 Choline C-11, diagnostic, per study dose, up to 20 millicuries	C-11 Choline Zevacor or In-facility production	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9516	lodine I-123 sod iodide mCi IODINE I-123 SODIUM IODIDE, DIAGNOSTIC, PER 100 MICROCURIES, UP TO 999 MICROCURIES	Dx I-123 Capsules. Use for A9516 for Thyroid uptakes and scans, for 1 mCi and greater and whole body imaging see A9509	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9517	I131 iodide cap, rx IODINE I-131 SODIUM IODIDE CAPSULE(S), THERAPEUTIC, PER MILLICURIE	Rx I-131 Capsules	1064	1064	К	К	\$23.73	\$23.73	0.0%
A9520	Tc99 Tilmanocept Diag 0.5MCI TECHNETIUM TC-99M TILMANOCEPT, DIAGNOSTIC, UP TO 0.5 MILLICURIES	Lymphoseek™	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9521	Tc99m exametazime TECHNETIUM TC-99M EXAMETAZIME, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES	CERETEC® HMPAO	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9524	I131 serum albumin, dx IODINE I-131 IODINATED SERUM ALBUMIN, DIAGNOSTIC, PER 5 MICROCURIES	I-131 Albumin	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9526	Nitrogen N-13 ammonia NITROGEN N-13 AMMONIA, DIAGNOSTIC, PER STUDY DOSE, UP TO 40 MILLICURIES	N-13	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9527	lodine I-125 sodium iodide IODINE I-125, SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE		2632	2632	U	U	\$61.13	\$43.13	41.7%

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
A9528	lodine I-131 iodide cap, dx IODINE I-131 SODIUM IODIDE CAPSULE(S), DIAGNOSTIC, PER MILLICURIE	I-131 Dx caps per mCi	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9529	I131 iodide sol, dx IODINE I-131 SODIUM IODIDE SOLUTION, DIAGNOSTIC, PER MILLICURIE	Dx I-131 sol per mCi	N/A	N/A	Z	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9530	I131 iodide sol, rx IODINE I-131 SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE	Rx I-131 sol per mCi	1150	1150	К	К	\$22.71	\$22.71	0.0%
A9531	I131 max 100uCi IODINE I-131 SODIUM IODIDE, DIAGNOSTIC, PER MICROCURIE (UP TO 100 MICROCURIES)	Dx I-131 up to 100 uCi	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9532	I125 serum albumin, dx IODINE I-125 SERUM ALBUMIN, DIAGNOSTIC, PER 5 MICROCURIES		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9536	Tc99m depreotide TECHNETIUM TC-99M DEPREOTIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 35 MILLICURIES	NEOTEC®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9537	Tc99m mebrofenin TECHNETIUM TC-99M MEBROFENIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES	CHOLETEC®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9538	Tc99m pyrophosphate TECHNETIUM TC-99M PYROPHOSPHATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES	PYROLITE® *Use this code for myocardial infarct imaging. Do not use this code for GBP, RVG or MUGA procedures see A9560	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9539	Tc99m pentetate TECHNETIUM TC-99M PENTETATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES	Tc-99m DTPA	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9540	Tc99m MAA TECHNETIUM TC-99M MACROAGGREGATED ALBUMIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MILLICURIES	MAA or new in 2020 see below Trade name: Pulmotech™ 5 vial carton NDC (69945- 139-20) or 30 vial carton: NDC (69945-139-40)	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9541	Tc99m sulfur colloid TECHNETIUM TC-99M SULFUR COLLOID, DIAGNOSTIC, PER STUDY DOSE, UP TO 20 MILLICURIES	SULFUR COLLOID® (SC)	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9542	In111 ibritumomab, dx INDIUM IN-111 IBRITUMOMAB TIUXETAN, DIAGNOSTIC, PER STUDY DOSE, UP TO 5 MILLICURIES	Dx In-111 ZEVALIN®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9543	Y90 ibritumomab, rx YTTRIUM Y-90 IBRITUMOMAB TIUXETAN, THERAPEUTIC, PER TREATMENT DOSE, UP TO 40 MILLICURIES	Rx Y-90 ZEVALIN®	1643	1643	к	К	\$65,476.58	\$65,476.58	0.0%
A9546	Co57/58 COBALT CO-57/58, CYANOCOBALAMIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 1 MICROCURIE	NYCOMED	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9547	In111 oxyquinoline INDIUM IN-111 OXYQUINOLINE, DIAGNOSTIC, PER 0.5 MILLICURIE	See new codes A9570 and A9571 for WBC and Platelet Imaging	N/A	N/A	Z	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
A9548	In111 pentetate INDIUM IN-111 PENTETATE, DIAGNOSTIC, PER 0.5 MILLICURIE	Indium DTPA	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9550	Tc99m gluceptate TECHNETIUM TC-99M SODIUM GLUCEPTATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES	GLUCOSCAN®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9551	Tc99m succimer TECHNETIUM TC-99M SUCCIMER, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MILLICURIES	DMSA	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9552	F18 fdg FLUORODEOXYGLUCOSE F-18 FDG, DIAGNOSTIC, PER STUDY DOSE, UP TO 45 MILLICURIES	FDG / F-18	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9553	Cr51 chromate CHROMIUM CR-51 SODIUM CHROMATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 250 MICROCURIES		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9554	I125 iothalamate, dx IODINE I-125 SODIUM IOTHALAMATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MICROCURIES		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9555	Rb82 rubidium RUBIDIUM RB-82, DIAGNOSTIC, PER STUDY DOSE, UP TO 60 MILLICURIES	Rb-82 CardioGen82	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9556	Ga67 gallium GALLIUM GA-67 CITRATE, DIAGNOSTIC, PER MILLICURIE	GALLIUM	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9557	Tc99m bicisate TECHNETIUM TC-99M BICISATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES	NEUROLITE®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9558	Xe133 xenon 10mci XENON XE-133 GAS, DIAGNOSTIC, PER 10 MILLICURIES	Xenon	N/A	N/A	N	Ν	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9559	Co57 cyano COBALT CO-57 CYANOCOBALAMIN, ORAL, DIAGNOSTIC, PER STUDY DOSE, UP TO 1 MICROCURIE	Shillings Study Rubratope 57 Cobatope 57	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9560	Tc99m labeled rbc TECHNETIUM TC-99M LABELED RED BLOOD CELLS, DIAGNOSTIC, PER STUDY DOSE, UP TO 30 MILLICURIES	ULTRATAG® or Cold PYP + 99m Tc Code to be used for both the invivo/invitro methods of tagging Red Blood Cells	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9561	Tc99m oxidronate TECHNETIUM TC-99M OXIDRONATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 30 MILLICURIES	HDP®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9562	Tc99m mertiatide TECHNETIUM TC-99M MERTIATIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES	MAG-3®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9563	P32 Na phosphate SODIUM PHOSPHATE P-32, THERAPEUTIC, PER MILLICURIE			1675	N	К	\$0.00	\$36.94	-100.0%
A9564	P32 chromic phosphate CHROMIC PHOSPHATE P-32 SUSPENSION, THERAPEUTIC, PER MILLICURIE	Phosphocol P- 32	N/A	N/A	E1	E1	N/A	N/A	N/A

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
A9566	Tc99m fanolesomab TECHNETIUM TC-99M FANOLESOMAB, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES	NeutroSpec™	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9567	Technetium TC-99m aerosol TECHNETIUM TC-99M PENTETATE, DIAGNOSTIC, AEROSOL, PER STUDY DOSE, UP TO 75 MILLICURIES	DTPA Aerosol For Lung Ventilation Studies	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9568	Technetium tc99m arcitumomab TECHNETIUM TC-99M ARCITUMOMAB, DIAGNOSTIC, PER STUDY DOSE, UP TO 45 MILLICURIES	CEA-SCAN®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9569	Technetium TC-99m auto WBC TECHNETIUM TC-99M EXAMETAZIME LABELED AUTOLOGOUS WHITE BLOOD CELLS, DIAGNOSTIC, PER STUDY DOSE	Use this code for infection or inflammation imaging do not use this code for brain imaging see A9521	N/A	N/A	Z	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9570	Indium In-111 auto WBC 'INDIUM IN-111 LABELED AUTOLOGOUS WHITE BLOOD CELLS, DIAGNOSTIC, PER STUDY DOSE	When prepared with patient WBC use this new code do not use A9547		N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9571	Indium IN-111 auto platelet INDIUM IN-111 LABELED AUTOLOGOUS PLATELETS, DIAGNOSTIC, PER STUDY DOSE	When prepared with patient platelets use this new code do not use A9547	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9572	Indium In-111 pentetreotide 'INDIUM IN-111 PENTETREOTIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 6 MILLICURIES	Octreoscan®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9580	Sodium Fluoride F-18, Sodium Fluoride F-18, diagnostic, per study dose, up to 30 millicuries	F-18, NaF, Sodium Fluoride	N/A	N/A	N	Ν	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9582	lodine i-123 iobenguane lobenguane, l-123, diagnostic, per study dose, up to 15 millicuries	I-123 MIBG AdreView NDC 17156-0235-01	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9584	lodine i-123 ioflupane lodine I-123 ioflupane, diagnostic, per study dose, (up to 5 millicuries)	DaTscan® NDC #17156-210-01	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9586	Florbetapir F18 FLORBETAPIR F18, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MILLICURIES	Amyvid [™] NDC #0002 1200-01 Passthrough: 10-1- 2018- 9-30-2022 legislation extended extra two years past the normal 3 years	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9587	Gallium ga-68, dotatate, diagnostic, 0.1 millicurie	(NETSPOT™), NDC (69488-001-40) AAA) FDA: approved (6/2/16) PET imaging agent for the localization of somatostatin receptor–positive neuroendocrine tumors Passthrough: 1-1-2017- 12- 31-2019	N/A	N/A	N	Z	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9588	Fluciclovine f-18, diagnostic, 1 millicurie	(Axumin™), Blue Earth Diagnostic (BED) FDA- approved (5/31/16), a PET imaging agent for detecting biochemical recurrence of prostate cancer Passthrough: 1-1-2017- 12-31- 2019	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
A9590	lodine 131 iobenguane, 1 millicurie	AZEDRA NDC# 71258-0015-02: Single-dose 30 rnl. vial of AZEDRA containing a total volume of 22.5 (±2.5) mt. of solution with a total radioactivity of 240-413 mcUvial (8.880-15.281 MBg/vial) radioactivity and calibration time Passthrough: 1-1-2019- 12-31-2021 then separate payment (K) therapeutic	9339	9339	К	К	\$329.72	\$338.48	-2.6%
•A9591 NEW Jan 1, 2021	Fluoroestradiol f 18 Fluoroestradiol F-18, diagnostic, 1 mCi	Trade name: CERIANNA™ NDC (72874-0001-01) For all payers, all settings, effective January 1, 2021. Pass-through End Date: September 30, 2023		9370	N	G	\$0.00	\$709.32	-100.0%
C9060 Use dates Oct 1, 2020 to December 31, 2020	Fluoroestradiol f 18 Fluoroestradiol F-18, diagnostic, 1 mCi	Trade name: CERIANNA™ NDC (72874-0001-01) Pass-through End Date: See A9591	9370	9370	D	D	N/A	N/A	Use for DOS Oct 1, 2020 to Dec 31, 2020 after see A9591
•A9592 NEW April 1, 2021	Cu-64 dototate diag Copper Cu-64, dotatate, diagnostic, 1 millicurie	Trade name: Detectnet™ Cu-64 DOTATATE NDC (69945-0064-01) Effective Jan 1, 2021 Pass-through End Date: December 31, 2023	Proposed to be packaged in CY 2024	9383	N	G	\$0.00	\$970.26	-100.0%
C9068 Use dates Jan 1, 2021 to March 31, 2021	Cu-64 dototate diag Copper Cu-64, dotatate, diagnostic, 1 millicurie	Trade name: Detectnet™ Cu-64 DOTATATE NDC (69945-0064-01) Effective Jan 1, 2021 to March 31, 2021. Pass-through End Date: see A9592	N/A	N/A	N/A	N/A	N/A	N/A	N/A
•A9593 NEW July 1, 2021	Gallium ga-68 psma-11 ucsf Gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie	No trade name UCSF Pass-through End Date: June 30, 2024	9409	9409	G	G	\$806.14	\$806.14	0.0%
•A9594 NEW July 1, 2021	Gallium ga-68 psma-11, ucla Gallium ga-68 psma-11, diagnostic, (ucla), 1 millicurie	No trade name UCLA Pass-through End Date: June 30, 2024	9410	9410	G	G	\$789.30	\$789.30	0.0%
•A9595 NEW January 1, 2022	Piflu f-18, dia 1 millicurie Piflufolastat f-18, diagnostic, 1 millicurie	Trade name: Pylarify™ PSMA NDC (71258-0022-00) Effective January 1, 2022 Pass-through End Date: December 31, 2024	9430	9430	G	G	\$580.35	\$580.35	0.0%
●A9596 NEW July 1, 2022	Gallium illuccix 1 millicure Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie	Trade name: Illuccox® GE FAST lab or Eckert & Ziegler GalliaPharm NDCs (74725-0100-25, 74725- 0100-64) Effective July 1, 2022 Pass-through End Date: June 30, 2025	9443	9443	G	G	\$996.40	\$996.40	0.0%
A9597	Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified	Generic code, use for newly FDA approved PET diagnostic radiopharmaceuticals	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9598	Positron emission tomography radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified	Generic code, use for newly FDA approved PET diagnostic radiopharmaceuticals	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
A9600	Strontium sr-89 chloride, therapeutic, per millicurie	Rx Metastron, Strontium, Strontium labeled metastron	0701	0701	К	К	\$4,146.34	\$4,156.57	-0.2%
•A9601 NEW July 1, 2022	Flortaucipir inj 1 millicurie Flortaucipir f 18 injection, diagnostic, 1 millicurie	Trade name: Tauvid ™ Eli Lilly and Company F-18 Flortaucipir NDCs (0002-1210-30, 0002- 1210-50, 0002-1220-48, 0002- 1220-50) Effective July 1, 2022 E2 = Pricing information not available to CMS No Pass-through at the time of publication	N/A	N/A	E2	E2	N/A	N/A	N/A

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
•A9602 NEW July 1, 2022	Fluorodopa f-18 diag per mci Fluorodopa f 18 injection, diagnostic, 1 millicurie	Trade name: None at time of print The Feinstein Institutes for Medical Research 350 Community Drive Manhasset New York 11030 Indicated for visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). NDC (13267-346-57) Effective Cobober 1, 2022	9053	9053	G	G	\$415.52	\$415.52	0.0%
A9604	Samarium sm-153 lexidronam, therapeutic, per treatment	Pass-through End Date: September 30, 2025 Rx Quadramet Samarium, Lexidronamm, 153Sm-	1295	1295	К	К	\$17,259.85	\$17,259.85	0.0%
A9606	dose, up to 150 millicuries Radium Ra-223 dichloride, therapeutic, per microcurie	EDTMP Xofigo™ NDC #50419- 0208-01	1745	1745	К	К	\$154.38	\$157.46	-2.0%
•A9607 NEW Oct 1, 2022	Lutetium lu 177 vipivotide Lutetium Lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	PLUVICTO™ Advanced Accelerator Applications USA, Inc NDCs (69488-003-01) Effective October 1, 2022 Pass-through End Date: September 30, 2025	9054	9054	G	G	\$225.25	\$229.70	-1.9%
A9699	Radiopharm rx agent noc RADIOPHARMACEUTICAL, THERAPEUTIC, NOT OTHERWISE CLASSIFIED	RX NOC	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
•C9067 NEW Oct 1, 2020	Gallium ga-68 dotatoc Gallium Ga-68, dotatoc, diagnostic, 0.01mCi	No trade name: UIHC C codes are Hospital Outpatient use only. Effective October 1, 2020 Pass-through End Date: September 30, 2023	Proposed to be packaged in CY 2024	9323	N	G	\$0.00	\$8.64	-100.0%
•A9800 NEW Oct 1, 2022	Gallium locametz 1 millicuri Gallium ga-68 gozetotide, diagnostic, (locametx), 1 millicurie	LOCAMETZ® Advanced Accelerator Applications USA, Inc NDCs (69488-003-01) Effective October 1, 2022 Pass-through End Date: September 30, 2025	9055	9055	G	G	\$873.44	\$871.50	0.2%
	DRUGs Often Used in I	Nuclear Medicine	Services	s, list is	not a	ll inclu	sive.		
J0153	Adenosine inj 1mg	ADENOSCAN Replaces J0150, J0151 and J0152	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J0280	Aminophyllin up to 250 MG, inj.		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J0461	Inj, atropine sulfate, 0.01 mg		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J1120	Acetazolamide sodium injection, up to 500 mg	Diamox	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J1160	Inj, digoxin, up to 0.5 mg	Lanoxin	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J1245	Dipyridamole injection, per 10mg	Persantine IV	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J1250	Inj dobutamine HCL/250 mg	Dobutrex	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J1265	Injection, dopamine HCl, 40 mg	Intropin	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates

CPT/		Trade	Proposed 2024	July 2023	Propo sed 2024	July 2023	Proposed 2024	July 2023	%
HCPCS	Description	Name	APC	APC	SI	SI	Payment Rate	Payment Rate	Change
J1610	Glucagon hydrochloride per 1MG	Glucagen	9042	9042	К	K	\$190.26	\$195.18	-2.5%
J1800	Propranolol HCL injection, up to 1 mg	Inderal	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J1940	Furosemide injection up to 20 mg	Lasix	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J2270	Morphine sulfate injection, up to 10 mg	Replaces J2271	N/A	N/A	Z	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J2785	Injection, Regadenoson <u>, 0.1 milligrams</u>	LexiScan NDC 00469- 6501-89	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J2805	Sincalide injection INJECTION, SINCALIDE, 5 MICROGRAMS	Kinevac®	N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J3240	Thyrotropin injection 0.9 mg n 1.1 mg vial	Thyrogen Thytropar	9108	9108	K	K	\$1,926.74	\$2,001.49	-3.7%
J3420	Injection, vitamin B-12 cyanocobalamin, up to 1000 mcg		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J7030	Normal saline solution infus (1000 CC)		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J7040	Normal saline solution infus (500ML=1)		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J7050	Normal saline solution infus (250 CC)		N/A	N/A	N	N	Packaged into APC rate	Packaged into APC rate	Providers should code and bill so costs are realized for future rates
J9311	Inj rituximab, hyaluronidase	RituXan	9467	9467	К	К	\$37.49	\$37.46	0.1%
J9312	lnj., rituximab, 10 mg	RituXan	9186	9186	К	К	\$81.19	\$81.04	0.2%
Q9968	Injection, non-radioactive, non-contrast, visualization adjunct (e.g., Methylene Blue, Isosulfan Blue), 1mg	Methylene Blue	1446	1446	К	К	\$7.40	\$7.72	-4.2%

Disclaimer

The opinions referenced are those of the members of the SNMMI Coding and Reimbursement Committee and their consultants based on their coding experience. They are based on the commonly used codes in Nuclear Medicine, which are not all inclusive. Always check with your local insurance carriers as policies vary by region. The final decision for the coding of a procedure must be made by the physician considering regulations of insurance carriers and any local, state or federal laws that apply to the physicians practice. The SNMMI and its representatives disclaim any liability arising from the use of these opinions.